Ipilimumab Clinical Trials

A listing of Ipilimumab medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 5 clinical trials
A Phase II Study to Evaluate the Safety Pharmacodynamics and Efficacy of Entinostat in Combination with Nivolumab plus Ipilimumab in Patients with Renal Cell Carcinoma Previously Treated with Nivolumab plus Ipilimumab

This study is being done to test the safety of combining Entinostat with Nivolumab and Ipilimumab. It will also measure the percentage of patients whose tumor shrank after receiving Entinostat with Nivolumab and Ipilimumab.

  • 0 views
  • 19 Feb, 2024
  • 1 location
Phase II Trial of Panitumumab Nivolumab and Ipilimumab for KRAS/NRAS/BRAF Wild-type MSS Refractory Metastatic Colorectal Adenocarcinoma

The purpose of this research study is to learn more about the safety and anti-cancer activity of a 3-drug combination therapy involving antibodies nivolumab, ipilimumab and panitumumab.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer: Big Ten Cancer Research Consortium. BTCRC-LUN17-127

This is an open-label Phase I/II study, with a dose escalation part (Phase I) and a 2-arm randomized part (Phase II), in patients with recurrent SCLC.

  • 0 views
  • 19 Feb, 2024
  • 1 location
A Phase 1/2 Study of Nivolumab in Children Adolescents and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab

The purpose of this study is to determine the side effects and best dose of nivolumab when given with or without ipilimumab to see how well they work in treating younger patients with solid tumors or sarcomas that have come back (recurrent) or do not respond to treatment (refractory).

  • 0 views
  • 19 Feb, 2024
  • 1 location
Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC): BTCRC-LUN16-081

The purpose of this study is to test the good and bad effects of the study drugs called nivolumab and ipilimumab when given after completing chemotherapy and radiation.

  • 0 views
  • 19 Feb, 2024
  • 1 location